Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for refractory non-infectious uveitis
ChiCTR2600117456Phase 4Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in noninfectious uveitis (NIU) comparing Control group: traditional therapy + placebo with Treatment group: traditional therapy + dapagliflozin (2 arms). Primary endpoint: Effect of reducing inflammation activity. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on ChiCTR2600117456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117456.